Medicinal products for human and investigational use / Derogations

This page is also available in

Parere del CESE: Medicinal products for human and investigational use / Derogations

The EESC:

  • welcomes this package of measures;
  • recognises that need to pay particular attention to the situation of smaller EU Member States, Cyprus, Ireland and Malta in particula;
  • stresses in particular the central role of a functioning, fair and efficient internal market;
  • welcomes the packaging requirements for UK products included in the package;
  • draws attention to the need for a timely and sustainable solution, which should be developed within the framework of the European Pharmaceutical Strategy.